Literature DB >> 3344760

Continuous 5-fluorouracil (5FU) infusion in carcinoma of the pancreas: a phase II study.

R Hansen1, E Quebbeman, P Ritch, C Chitambar, T Anderson.   

Abstract

UNLABELLED: Sixteen patients with metastatic carcinoma of the pancreas were treated with continuous ambulatory 5-Fluorouracil (5FU) infusion (200-300 mg/m2/day) through a chronic indwelling central venous catheter. Twelve of sixteen patients (75%) had two or more sites of disease, and eleven of sixteen (69%) had liver metastases. Five patients had previous chemotherapy.
RESULTS: partial remission, 3/16 (19%); stable disease, 8/16 (50%); and progressive disease, 5/16 (31%). Improvement in ECOG performance status was observed in 2/3 responding and 6/8 stable disease patients, respectively. Toxicities included hand-foot syndrome, mucositis, diarrhea, and cerebellar ataxia, which required treatment interruption in 9/16 patients (56%). No myelosuppression or catheter related problems were seen. The authors conclude that continuous infusion 5FU is a potentially efficacious palliative therapy in the management of carcinoma of the pancreas.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3344760     DOI: 10.1097/00000441-198802000-00001

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  10 in total

Review 1.  Drug-induced cerebellar ataxia: a systematic review.

Authors:  J van Gaalen; F G Kerstens; R P P W M Maas; L Härmark; B P C van de Warrenburg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

Review 2.  Rationale and appropriate use of chemotherapy and radiotherapy for pancreatic ductal adenocarcinoma.

Authors:  Robert de W Marsh; Thomas George
Journal:  Curr Gastroenterol Rep       Date:  2006-04

3.  Investigational Strategies for Detection and Intervention in Early-Stage Pancreatic Cancer. April 24-27, Annapolis, Maryland. Abstracts.

Authors: 
Journal:  Int J Pancreatol       Date:  1994 Oct-Dec

4.  Intra-arterial continuous infusion for treatment of pancreatic and biliary tract cancer.

Authors:  C Zanon; O Alabiso; M Grosso; R Buosi; I Chiappino; R Clara; A Satolli; S Zai; M Bortolini; M Botta; A Mussa
Journal:  Int J Pancreatol       Date:  2000-06

5.  Usefulness of contrast-enhanced ultrasonography in determining treatment efficacy and outcome after pancreatic cancer chemotherapy.

Authors:  Atsushi Sofuni; Takao Itoi; Fumihide Itokawa; Takayoshi Tsuchiya; Toshio Kurihara; Kentaro Ishii; Syujiro Tsuji; Nobuhito Ikeuchi; Fuminori Moriyasu
Journal:  World J Gastroenterol       Date:  2008-12-21       Impact factor: 5.742

Review 6.  Pancreatic cancer: advances in treatment.

Authors:  Somala Mohammed; George Van Buren; William E Fisher
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

7.  A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma.

Authors:  J J Arends; H P Sleeboom; M B L Leys; D Ten Bokkel Huinink; R S de Jong; J M Smit; J W R Nortier; M E T Tesselaar
Journal:  Br J Cancer       Date:  2005-02-14       Impact factor: 7.640

8.  Antitumor Effects of Cannabinoids in Human Pancreatic Ductal Adenocarcinoma Cell Line (Capan-2)-Derived Xenograft Mouse Model.

Authors:  Siriwan Sakarin; Nuntana Meesiripan; Suleeporn Sangrajrang; Nuntakan Suwanpidokkul; Piyaporn Prayakprom; Chatchada Bodhibukkana; Vipada Khaowroongrueng; Kankanit Suriyachan; Somchai Thanasittichai; Attasit Srisubat; Pattamaporn Surawongsin; Kasem Rattanapinyopituk
Journal:  Front Vet Sci       Date:  2022-07-22

9.  Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC).

Authors:  F Di Costanzo; P Carlini; L Doni; B Massidda; R Mattioli; A Iop; E Barletta; L Moscetti; F Recchia; P Tralongo; S Gasperoni
Journal:  Br J Cancer       Date:  2005-07-25       Impact factor: 7.640

Review 10.  Distal bile duct carcinomas and pancreatic ductal adenocarcinomas: postulating a common tumor entity.

Authors:  Rosa B Schmuck; Cynthia V de Carvalho-Fischer; Christopher Neumann; Johann Pratschke; Marcus Bahra
Journal:  Cancer Med       Date:  2015-12-09       Impact factor: 4.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.